Key Takeaways
- • A Cayman Islands court ruled Friday that Seth Harrison, general partner of biotech venture capital firm Apple Tree Partners (ATP), must relinquish control of the fund, marking an escalation in a prolonged dispute with major backer Rigmora Biotech Investors.
- • Court-appointed independent directors Alexander Lawson and Barry Lynch of Alvarez & Marsal are positioned to assume management of ATP, which has deployed capital from Russian billionaire Dmitry Rybolovlev's family trust into biotech startups since 2012.
- • Rybolovlev's trust originally committed up to $1.5 billion to fund ATP's biotech investments, with capital deployed to portfolio companies including Intergalactic Therapeutics and Red Queen Therapeutics, as well as the acquired Akero Therapeutics.
- • The legal dispute intensified after ATP sued Rigmora in Delaware Chancery Court last year, alleging the primary backer "failed to meet its capital commitments," while Rigmora countersued in the Cayman Islands demanding ATP be wound down over alleged fund mismanagement.
- • A separate U.S. bankruptcy court proceeding remains active, with ATP pursuing a restructuring plan to continue funding portfolio companies, while Harrison has emerged as a bidder for those startups.
Summary
A Cayman Islands court has stripped Seth Harrison of control over Apple Tree Partners, a biotech-focused venture capital firm that has managed over a decade of capital deployment from prominent investors. The Friday ruling represents a significant turning point in a contentious legal battle that has unfolded across multiple jurisdictions and resulted in bankruptcy proceedings. The decision mandates that Harrison step aside in favor of two court-appointed independent directors—Alexander Lawson and Barry Lynch of consulting firm Alvarez & Marsal—who will assume operational oversight of the fund.
The dispute centers on a fractured relationship between ATP and Rigmora Biotech Investors, which is associated with Russian billionaire Dmitry Rybolovlev. The family trust became ATP's anchor investor in 2012 by committing up to $1.5 billion to fund biotech investments. Over the subsequent 14 years, this capital was deployed across multiple portfolio companies and acquisitions, including Intergalactic Therapeutics, Red Queen Therapeutics, and Akero Therapeutics. However, the relationship deteriorated significantly, triggering dual legal actions in separate courts.
ATP initiated litigation in Delaware Chancery Court last year, alleging that Rigmora "failed to meet its capital commitments" by withholding cash pledged to portfolio companies. Rigmora responded with its own Cayman Islands lawsuit, asserting that ATP had mismanaged funds and should be liquidated. The Cayman Islands ruling now places fund management under court supervision through appointed independent directors, effectively sidelining Harrison from operational decision-making authority.
Complicating the situation further, a U.S. bankruptcy court proceeding remains ongoing, in which ATP is pursuing a restructuring plan designed to enable continued funding of its portfolio companies. In a notable development, Harrison has positioned himself as a bidder for ATP's startup portfolio, according to a firm spokesperson, suggesting potential paths for him to maintain involvement with the underlying investments despite his loss of fund management control.
The dispute centers on a fractured relationship between ATP and Rigmora Biotech Investors, which is associated with Russian billionaire Dmitry Rybolovlev. The family trust became ATP's anchor investor in 2012 by committing up to $1.5 billion to fund biotech investments. Over the subsequent 14 years, this capital was deployed across multiple portfolio companies and acquisitions, including Intergalactic Therapeutics, Red Queen Therapeutics, and Akero Therapeutics. However, the relationship deteriorated significantly, triggering dual legal actions in separate courts.
ATP initiated litigation in Delaware Chancery Court last year, alleging that Rigmora "failed to meet its capital commitments" by withholding cash pledged to portfolio companies. Rigmora responded with its own Cayman Islands lawsuit, asserting that ATP had mismanaged funds and should be liquidated. The Cayman Islands ruling now places fund management under court supervision through appointed independent directors, effectively sidelining Harrison from operational decision-making authority.
Complicating the situation further, a U.S. bankruptcy court proceeding remains ongoing, in which ATP is pursuing a restructuring plan designed to enable continued funding of its portfolio companies. In a notable development, Harrison has positioned himself as a bidder for ATP's startup portfolio, according to a firm spokesperson, suggesting potential paths for him to maintain involvement with the underlying investments despite his loss of fund management control.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.